Malin Corporation PLC
ISEQ:MLC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.34
6.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Malin Corporation PLC
Net Issuance of Debt
Malin Corporation PLC
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Malin Corporation PLC
ISEQ:MLC
|
Net Issuance of Debt
-€200k
|
CAGR 3-Years
85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ICON PLC
NASDAQ:ICLR
|
Net Issuance of Debt
-$635.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Malin Corporation PLC
Glance View
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.
See Also
What is Malin Corporation PLC's Net Issuance of Debt?
Net Issuance of Debt
-200k
EUR
Based on the financial report for Jun 30, 2024, Malin Corporation PLC's Net Issuance of Debt amounts to -200k EUR.
What is Malin Corporation PLC's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
85%
Over the last year, the Net Issuance of Debt growth was 0%. The average annual Net Issuance of Debt growth rates for Malin Corporation PLC have been 85% over the past three years .
You don't have any saved screeners yet
